Modified hemofiltration method for clearing peripheral α-synuclein aggregates in patient with neurodegenerative disease

A modified hemofiltration method for clearing peripheral α-synuclein aggregates in a patient with a neurodegenerative disease, comprising the following steps:

• detecting a concentration of α-synuclein in a blood sample of the patient by an enzyme-linked immunosorbent assay using two different monoclonal anti-α-synuclein antibodies, the two different monoclonal anti-α-synuclein antibodies comprising an anti-α-synuclein monoclonal antibody as a capture antibody and a biotinylated mouse anti-human α-synuclein monoclonal antibody as an assay antibody, and calculating a ratio (S) representing a proportion of α-synuclein dimers relative to total α-synuclein;
• performing the hemofiltration to determine a blood flow velocity, exchange membrane aperture (D) and an exchange membrane area for the hemofiltration of the patient with the neurodegenerative disease;
• analyzing a correlation between the ratio (S) of the α-synuclein dimers and the exchange membrane aperture (D), wherein the exchange membrane aperture (D) represents a membrane pore diameter required to achieve the hemofiltration according to the ratio (S) of the patient, and building a calculation model for the ratio (S) and the exchange membrane aperture (D);
• and
• performing the hemofiltration on the patient with the neurodegenerative disease based on the ratio (S) of the α-synuclein dimers and the exchange membrane aperture (D) determined by the calculation model to find a clearance rate of the peripheral α-synuclein aggregates, wherein the hemofiltration comprises three sessions of two hours each, and evaluating treatment efficacy by measuring post-treatment cerebrospinal fluid α-synuclein concentration and a clinical motor-function score of the neurodegenerative disease.